Showing results (131-140 of 163) with videos related to

Sort By:
Pageof 17
The Lancet. Oncology|November 8, 2015
Immunotherapy response assessment in neuro-oncology: a report of the RANO working groupHideho Okada, Michael Weller, Raymond Huang, et al.
International Journal of Radiation Oncology, Biology, Physics|July 26, 2006
Salvage treatment for childhood ependymoma after surgery only: Pitfalls of omitting "at once" adjuvant treatmentMaura Massimino, Felice Giangaspero, Maria Luisa Garrè, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2016
Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker AnalysesTimothy Cloughesy, Gaetano Finocchiaro, Cristóbal Belda-Iniesta, et al.
Nature Genetics|June 9, 2016
Clonal evolution of glioblastoma under therapyJiguang Wang, Emanuela Cazzato, Erik Ladewig, et al.
The Oncologist|September 30, 2018
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent GlioblastomaAlba A Brandes, Miguel Gil-Gil, Frank Saran, et al.
Cell Death Discovery|April 13, 2026
BIRC3/CAV1 co-expression drives GBM aggressiveness as a prognostic signature and therapeutic vulnerabilitySara Franceschi, Mariangela Morelli, Francesca Lessi, et al.
Science (New York, N.Y.)|July 28, 2012
Transforming fusions of FGFR and TACC genes in human glioblastomaDevendra Singh, Joseph Minhow Chan, Pietro Zoppoli, et al.
Neuro-Oncology|May 5, 2022
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoterMichael Lim, Michael Weller, Ahmed Idbaih, et al.
Acta Neuropathologica|December 8, 2023
A new subtype of diffuse midline glioma, H3 K27 and BRAF/FGFR1 co-altered: a clinico-radiological and histomolecular characterisationLucie Auffret, Yassine Ajlil, Arnault Tauziède-Espariat, et al.
Neuro-Oncology Advances|May 30, 2024
TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive gliomaAlberto Picca, Anna Luisa Di Stefano, Julien Savatovsky, et al.
Pageof 17